Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer's disease.
about
Interactions of metals and Apolipoprotein E in Alzheimer's diseaseAPOE genotype and stress response - a mini reviewApolipoprotein E and Alzheimer disease: risk, mechanisms and therapyThe binding of apolipoprotein E to oligomers and fibrils of amyloid-β alters the kinetics of amyloid aggregation.Cerebrospinal fluid-induced retardation of amyloid β aggregation correlates with Alzheimer's disease and the APOE ε4 allele.Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer's Disease Prevention and Early InterventionAlzheimer's disease: relevant molecular and physiopathological events affecting amyloid-β brain balance and the putative role of PPARs.ApoE: In Vitro Studies of a Small Molecule Effector.ApoE4-specific Misfolded Intermediate Identified by Molecular Dynamics Simulations.Cholesterol: its regulation and role in central nervous system disorders.Structural Stability and Local Dynamics in Disease-Causing Mutants of Human Apolipoprotein A-I: What Makes the Protein Amyloidogenic?A Dietary Treatment Improves Cerebral Blood Flow and Brain Connectivity in Aging apoE4 MiceInteraction of ApoE3 and ApoE4 isoforms with an ITM2b/BRI2 mutation linked to the Alzheimer disease-like Danish dementia: Effects on learning and memoryTranscriptional regulation and its misregulation in Alzheimer's disease.Apolipoprotein E as a β-amyloid-independent factor in Alzheimer's disease.ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer's disease.Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's diseaseIncreased Aβ42-α7-like nicotinic acetylcholine receptor complex level in lymphocytes is associated with apolipoprotein E4-driven Alzheimer's disease pathogenesis.APOEε4 Genotype and Hypertension Modify 8-year Cortical Thinning: Five Occasion Evidence from the Seattle Longitudinal Study.Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease.Human ApoE ɛ2 Promotes Regulatory Mechanisms of Bioenergetic and Synaptic Function in Female Brain: A Focus on V-type H+-ATPase.Concerning the structure of apoEFluorescence study of domain structure and lipid interaction of human apolipoproteins E3 and E4.ApoE: the role of conserved residues in defining functionHelical structure, stability, and dynamics in human apolipoprotein E3 and E4 by hydrogen exchange and mass spectrometry.Novel natural structure corrector of ApoE4 for checking Alzheimer's disease: benefits from high throughput screening and molecular dynamics simulations.Atomistic Insights into Structural Differences between E3 and E4 Isoforms of Apolipoprotein E.Molecular Mechanisms of the R61T Mutation in Apolipoprotein E4: A Dynamic Rescue.Differential Aging Trajectories of Modulation of Activation to Cognitive Challenge in APOE ε4 Groups: Reduced Modulation Predicts Poorer Cognitive Performance.NKp44-Derived Peptide Binds Proliferating Cell Nuclear Antigen and Mediates Tumor Cell Death.The Role of Genetics in Advancing Precision Medicine for Alzheimer's Disease-A Narrative Review.
P2860
Q21131068-743E6216-756B-407E-8C32-F19273AAD8F6Q26741633-C45A2968-C482-4371-922B-E8D75AB20F60Q28282855-A9D7B9E0-7089-424D-B871-E7F386BCBFBFQ30032680-A1D2D866-5CC6-4B90-A93D-987B919F4253Q33363912-9ED83CF1-1025-4353-B67A-3C61E2431461Q33838291-18D036B6-2594-4837-9C44-148007346254Q33959032-D5F79C0C-F71D-49A2-BAC2-0506C7484376Q34521552-BA88883A-D10C-4137-9163-DEF96350FFC9Q35823248-DA71904D-A220-4FD5-A474-5766F46E9249Q36355194-ABA407C9-53B2-43BC-89EB-03B7D4FC927AQ36553540-6570108E-3284-4AA6-8B88-912AD6B05FA7Q36724664-C04175A9-4775-4B86-A972-1C1C93B4A0F9Q36988218-AF7C1C90-D026-44EC-AD6D-B8406A497732Q37370537-ACF6AA28-D09D-446F-A659-600031930634Q37691070-F5B17FFD-EA95-4AC7-8D75-A96009947BEEQ37716948-E5ABE0CE-E28F-436B-B6BB-63133B94F88DQ38197948-5A36F986-23AE-4A4C-9A69-C7FFF5DEBB8CQ38657053-D2C28FD7-F0D5-4108-9F4B-AE5A47C15924Q38819201-8CF79D6D-A087-46D3-A17B-195FDD6A1E1BQ39257249-8C76E34F-CB07-46B4-9131-AEFE08109AE8Q39657626-6D71F273-CCD7-4214-B22E-5816DEF894CEQ41836439-3F547AF8-816C-4C90-B40E-A3F1B3D87837Q42174067-23187F46-9BB0-4966-B526-520525AD77FCQ42185078-FEE914CF-282F-464A-BDBB-57A2209EC96FQ42323951-4209F119-43DC-4CCF-A16B-D567623B5B2BQ42857729-40BA50B3-8F5D-4867-BD87-B0CD86798526Q47270627-C31CC879-8AAE-4763-8319-10433227BEBBQ47794190-A2D45353-50A1-4664-AC15-31714B7C3C5FQ48220193-67F902C1-6A38-4777-8381-9238871EAA1FQ55020290-79254F48-9846-4967-89CC-7A5B827F465AQ55381143-A259474F-CDE0-4F1A-8667-95C5FD136320
P2860
Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer's disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Structural differences between ...... gents for Alzheimer's disease.
@ast
Structural differences between ...... gents for Alzheimer's disease.
@en
type
label
Structural differences between ...... gents for Alzheimer's disease.
@ast
Structural differences between ...... gents for Alzheimer's disease.
@en
prefLabel
Structural differences between ...... gents for Alzheimer's disease.
@ast
Structural differences between ...... gents for Alzheimer's disease.
@en
P2860
P356
P1476
Structural differences between ...... gents for Alzheimer's disease.
@en
P2093
Carl Frieden
Kanchan Garai
P2860
P304
P356
10.1073/PNAS.1207022109
P407
P577
2012-05-21T00:00:00Z